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a  b  s  t  r  a  c  t
Measurement  of  RNA  can  be  used  to study  and  monitor  a  range  of infectious  and  non-communicable
diseases,  with  proﬁling  of multiple  gene  expression  mRNA  transcripts  being  increasingly  applied  to  can-
cer stratiﬁcation  and  prognosis.  An international  comparison  study  (Consultative  Committee  for  Amount
of  Substance  (CCQM)-P103.1)  was  performed  in  order  to evaluate  the  comparability  of  measurements
of  RNA  copy  number  ratio  for multiple  gene  targets  between  two samples.  Six exogenous  synthetic
targets  comprising  of  External  RNA Control  Consortium  (ERCC)  standards  were  measured  alongside
transcripts  for three  endogenous  gene  targets  present  in  the  background  of human  cell  line  RNA.  The
study  was  carried  out  under  the  auspices  of  the  Nucleic  Acids  (formerly  Bioanalysis)  Working  Group  of
the CCQM.  It was  coordinated  by LGC  (United  Kingdom)  with  the  support  of  National  Institute  of  Stan-
dards  and Technology  (USA)  and results  were  submitted  from  thirteen  National  Metrology  Institutes  andormalisation Designated  Institutes.  The  majority  of  laboratories  performed  RNA  measurements  using RT-qPCR,  with
tandardisation datasets  also being  submitted  by  two laboratories  based  on reverse  transcription  digital  polymerase
olecular diagnostic
ranscriptomics
ancer
iagnostics
iomarker identiﬁcation and validation
chain  reaction  and  one  laboratory  using  a  next-generation  sequencing  method.  In RT-qPCR  analysis,
the  RNA  copy  number  ratios  between  the two  samples  were  quantiﬁed  using  either  a standard  curve
or  a relative  quantiﬁcation  approach.  In general,  good  agreement  was  observed  between  the  reported
results  of  ERCC  RNA  copy  number  ratio  measurements.  Measurements  of  the RNA  copy  number  ratios  for
endogenous  genes  between  the  two  samples  were  also  consistent  between  the  majority  of laboratories.
∗ Corresponding author.
E-mail address: alison.devonshire@lgcgroup.com (A.S. Devonshire).
ttp://dx.doi.org/10.1016/j.bdq.2016.05.003
214-7535/© 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
.0/).
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Some  differences  in the reported  values  and  conﬁdence  intervals  (‘measurement  uncertainties’)  were
noted  which  may  be attributable  to  choice  of  measurement  method  or quantiﬁcation  approach.  This
highlights the  need  for  standardised  practices  for the  calculation  of  fold  change  ratios  and  uncertainties
in the area  of  gene  expression  proﬁling.
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. Introduction
Gene expression proﬁling typically involves measuring the rel-
tive amounts of messenger RNA (mRNA) present in two or more
amples or conditions. Such proﬁling is used to distinguish between
isease states or show how cells in vitro react to particular treat-
ents. RNA transcripts, therefore, offer considerable potential as
iagnostic and prognostic biomarkers. However, RNA measure-
ent is challenging and complicated by difﬁculties associated with
he robustness and comparability of the techniques used to analyse
hese molecules and lack of commonly applied universal standards.
he set of external RNA controls developed through the External
NA Controls Consortium (ERCC),1 an ad hoc group of 70 members
rom private, public and academic organizations led by the National
nstitute of Standards (NIST), was developed in order to meet the
ioanalytical community’s need for measurement assurance tools
or reproducible gene expression measurements [1]. The panel of
6 different plasmid standards developed through the ERCC project
onsists of artiﬁcial sequences or sequences from bacterial and
ther genomes which lack homology to human sequences and from
hich RNA controls are produced by in vitro transcription [2]. These
tandards have been tested as prototype quality control tools for
ene expression measurements and applied to the validation of
ew qPCR and sequencing approaches [3–6].
Whilst measurement of a single gene transcript is applicable
o the diagnosis of some diseases [7], there are increasing diag-
ostic opportunities when multiple gene transcripts are analysed.
he transcriptome changes during disease and the changes can be
easured as a surrogate biomarker to diagnose a given pathology.
easuring panels of biomarkers offers a more powerful and infor-
ative approach, but also considerably increases the measurement
hallenge, due to differing properties (e.g. speciﬁcity) in the detec-
ion chemistries for each biomarker and increased complexity in
ownstream data analysis. In some cases, accurate quantiﬁcation
f multiple individual transcripts is required, although more fre-
uently it is the change in the overall pattern of expression (i.e.
he gene expression signature) that is the diagnostic or prognostic
ndicator. In these instances, indicators use a score based on the
NA copy number ratios of multiple targets or determine proﬁle
imilarity based on cluster analysis [8].Wider implementation of prognostic and predictive tests util-
sing gene expression measurements of multiple markers is
nticipated for a number of conditions, including breast cancer
1 Abbreviations: cancer susceptibility candidate 3 (CASC3), Consultative Commit-
ee  for Amount of Substance (CCQM), decimal places (d.p.), droplet-dPCR (ddPCR),
xternal RNA Controls Consortium (ERCC), gene of interest (GOI), hypoxanthine
uanine phosphoribosyltransferase 1 (HPRT1), long-term stability (LTS), matrix
etallopeptidase 1 (MMP1), measurement uncertainty (MU), median absolute devi-
tion (MAD), National Institute of Standards (NIST), National Measurement Institute
NMI), nestin (NES), next generation sequencing (NGS), quantiﬁcation cycle (Cq),
elative quantiﬁcation (RQ), relative standard deviation (RSD), reverse transcription-
igital polymerase chain reaction (RT-dPCR), reverse transcription-quantitative
olymerase chain reaction (RT-qPCR), RNA integrity number (RIN), short-term
tability (STS), signiﬁcant ﬁgures (s.f.), solute carrier family 1 (glial high afﬁnity
lutamate transporter) member 3 (SLC1A3), standard curve (SC), ubiquitin C (UBC),
nknown 1 (U1), Unknown 2 (U2). by  Elsevier  GmbH.  This  is  an open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
[9], colorectal cancer [10] and coronary artery disease [11]. A
number of gene expression tests have been developed for person-
alised prognosis of early stage breast cancer [12], some of which
are conducted at a central laboratory while the recently devel-
oped EndoPredict assay is suitable for implementation in multiple
regional laboratories [13]. This raises the issue of how to ensure
comparability of the underlying RNA copy number ratio values
(which is calculated based on differences in the quantiﬁcation cycle
(Cq; formerly threshold cycle Ct or crossing point Cp) in the case of
RT-qPCR measurements [14]) and the calculated prognostic scores
between alternative tests [15]. In order to assess the accuracy (i.e.
closeness of agreement between a measured quantity value and
a true quantity value [16]) of measurements by different labora-
tories or different assays through round-robin or external quality
assessment schemes [13], samples with independently assigned
reference values would be required. For value assignment of con-
trol samples in terms of RNA copy number ratio, analytical methods
of high accuracy and inter-laboratory reproducibility (precision of
measurements when performed at different locations, by different
operators or using different platforms [16]), are required (so called
reference methods [17]), where sources of error are well under-
stood and can be captured in a measurement uncertainty budget
[18]. While one study assessed the reproducibility of the Oncotype
Dx multiple gene signature test for recurrence prognosis and ther-
apeutic response prediction in breast cancer, this was restricted to
comparisons between different operators within the same labora-
tory [19]. Others have addressed the question of inter-laboratory
reproducibility, but have only evaluated a single target with large
(several orders of magnitude) changes in expression [7]. The suit-
ability of methods for RNA analysis to fulﬁl the function of reference
methods for multiparametric gene expression signatures has not
previously been evaluated.
In the current study CCQM-P103.1, the accuracy and inter-
laboratory reproducibility of RNA biomarker measurements was
assessed by comparing multiple RNA copy number ratios and
associated measurement uncertainties of a panel of six ERCC syn-
thetic transcripts spiked into a complex RNA background. Three
endogenous RNA targets present within the complex background,
consisting of total RNA from three commonly used human liver,
brain and bone cell lines, were also selected as ‘genes of interest’
(GOIs) and some participating laboratories measured these along-
side the synthetic transcripts. Laboratories reported the RNA copy
number ratio (the measurand) of each target transcript between
two unknown samples (Unknown 1, U1, and Unknown 2, U2). Lab-
oratories could use the method of their choice; the coordinating
laboratory provided participating institutes with information on
the RT-qPCR method and primer/probe sequences to nine mRNA
targets which had been used in the development of the study mate-
rials and information on possible normalisation approaches for
the endogenous GOIs (Supplementary information A). Participating
National Measurement Institutes (NMIs) were not obliged to follow
this and performed measurements and calculations independently
for the purpose of developing and demonstrating capability in this
ﬁeld of measurements. The majority of laboratories used a reverse
transcription quantitative polymerase chain reaction (RT-qPCR)
approach, whilst two laboratories analysed the study materials
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sing reverse transcription digital polymerase chain reaction (RT-
PCR), a binary-counting method based on limiting dilution [20,21].
wo dPCR platforms were utilised with one laboratory using
icroﬂuidic dPCR arrays, which partition each sample into over
00 sub-nanolitre-scale reaction chambers [22], and another lab-
ratory a droplet-dPCR (ddPCR) system, which partitions samples
nto approximately 20,000 sub-nanolitre-scale emulsion droplets
23]. In addition, one laboratory examined the study materials using
 next generation sequencing (NGS) method for whole transcrip-
ome sequencing (RNA-Seq) [24] to obtain further insights into the
ccuracy of NGS methods for quantitative expression proﬁling.
. Materials and methods
.1. Preparation of test materials
Each ERCC plasmid DNA (ERCC-00013, -00025, -00042, -00099,
00113 and -00171)(NIST) was linearised and in vitro transcribed
sing a Megascript T7 kit (Ambion) to produce corresponding ERCC
NA stock solution. Following in-solution DNase treatment (Turbo
Nase, Ambion) and clean-up using an RNeasy Mini Kit (Qiagen)
ith on-column DNase treatment, the concentration (ng/L) of
ach transcript stock solution was measured using the Nanodrop
000 spectrophotometer (Thermo Scientiﬁc). RNA copy number
er L (copies/L) of each ERCC in the solution was estimated based
n the molecular weight of each transcript and the Avogadro num-
er. The identity and purity of each in vitro transcribed ERCC was
onﬁrmed by electrophoresis using the 2100 Bioanalyzer (Agilent);
urity was estimated based on the presence of speciﬁc and non-
peciﬁc length fragments in the Bioanalyzer traces and taken into
onsideration for assignment of RNA copy number concentration
n the Calibrant material (Section 2.4.1).
Endogenous genes of interest matrix metallopeptidase 1
MMP1); nestin (NES); and solute carrier family 1 (glial high afﬁn-
ty glutamate transporter) member 3 (SLC1A3) were expressed to
iffering extents in three different cell lines: hepatoma Hep-G2,
ligodendroglioma Hs 683 and osteosarcoma SaOS-2 cells (ATCC).
ell lines were maintained under supplier’s recommended culture
onditions. Total RNA was extracted using TRIzol reagent (Invitro-
en) and genomic DNA was removed using DNase (Ambion, rDNase
). RNA was puriﬁed using an RNeasy Midi kit (Qiagen). RNA quan-
ity and quality were assessed using Nanodrop 1000 and 2100
ioanalyzer, respectively. A260/280 and A260/230 ratios >2.0 and
NA integrity number (RIN) of ≥9.3 conﬁrmed high purity and
ntegrity of total RNA.
Each ERCC RNA stock solution was diluted in RNA Storage Solu-
ion (Ambion) to 109 copies/L (for Calibrant) or 108 copies/L
for U1, U2) and different volumes of these solutions were mixed
o produce three 100× ERCC solutions each containing all six ERCC
ranscripts at 100 times the ﬁnal concentration (further informa-
ion contained in Supplementary information Section B). Each cell
ine RNA stock solution was diluted in RNA Storage Solution to ﬁxed
oncentrations and three ‘mixed ratio cell line’ solutions for U1, U2
nd Calibrant, were prepared by mixing different proportions of
ach cell line RNA to a ﬁnal concentration of 50 ng/L. Each 100×
RCC solution was spiked into the corresponding ‘mixed ratio cell
ine’ solution to produce U1, U2 and Calibrant materials. The U1,
2 and Calibrant solutions were aliquoted (150 L) to generate 245
nits of each material.
.2. Stability of test materialsA short-term stability (STS) study was undertaken at a range
f temperatures to establish the ﬁdelity of unit composition dur-
ng sample distribution. Study materials Calibrant, U1 and U2 weren and Quantiﬁcation 8 (2016) 15–28 17
maintained at −80 ◦C (reference temperature), or on dry ice, 4 ◦C
and 40 ◦C for time (T) 0, 7 and 14 days (three replicate units per
temperature and time point). Immediately following incubation
at designated temperatures, units were tested isochronously by
RT-qPCR (50 ng per reaction) for one ERCC (ERCC-00099) and one
reference gene (hypoxanthine guanine phosphoribosyltransferase
1, HPRT1) (n = 1 assay/unit). These analytes were chosen to rep-
resent exogenous and endogenous transcripts, respectively, in the
stability study. RT-qPCR was  performed by the coordinating labora-
tory as described in the Study Protocol, Supplementary information
A. Cq values (Supplementary information B, Fig. B.1) were analysed
by ﬁtting a linear model to each assay and sample combination,
with time and temperature as the covariates, using R version 3.1.1
[25]. As the aim of this analysis was to establish whether the Cq
value varied with storage time, the time variate was treated as a
continuous variable.
A long-term stability (LTS) study was also performed in order to
ascertain whether the study materials remained stable when stored
at −20 ◦C in the case that −80 ◦C storage, which is the standard stor-
age temperature for RNA-based materials, was not available in the
participating laboratories. Three replicate units for each Calibrant,
U1 and U2 were incubated for one week on dry ice (to simulate
the shipping period) before being transferred to either −80 ◦C or
−20 ◦C for six months. Measurements of ERCC-00099 and HPRT1
were made following 6 months storage using the same RT-qPCR
approach used for the STS. The Cq values for a particular unit type
at the two temperatures (Supplementary information B, Fig. B.2)
were compared by ANOVA using R version 2.14.1.
2.3. Homogeneity of test materials
Sample homogeneity was  evaluated for Calibrant, U1 and U2
units. Eight technical replicates from ten units were analysed
by one-step RT-qPCR for ERCC-00099 and HPRT1 (Supplemen-
tary information B, Fig. B.3) and data analysed using R version
2.13.1. A preliminary check for effects of RT-qPCR plate loca-
tion (row and column) was  performed using linear modelling
[26]. One plate (U2/HPRT1) showed a statistically signiﬁcant row
effect (p = 0.003); another (U1/ERCC-99) showed a signiﬁcant col-
umn  effect (p = 0.025, increasing to 0.06 on outlier removal).
Plate U1/HPRT1 showed a strongly signiﬁcant column effect
(p = 0.002) on removal of the outlier in the set, and a marginal
effect (p = 0.0502) otherwise. Therefore within- and between-unit
components of variance in Cq data were obtained by restricted max-
imum likelihood estimation using a mixed effects model in which
RT-qPCR plate row and column were taken as ﬁxed effects and
sample ID (unit or tube) as random effects [27].
2.4. ERCC assigned values and uncertainties
2.4.1. RNA copy number
ERCC RNA copy number values and uncertainties for Calibrant
and Unknown materials were calculated taking into account the
following factors: stock concentration, material integrity (purity,
homogeneity, stability) and volumetric dilution of the stock solu-
tion (for example calculation, see Supplementary information C,
Table C.1).
The standard uncertainty for stock concentration was estimated
based on replicate measurements of the speciﬁc ERCC stock solu-
tion together with an allowance for between-day variation based
on previous ﬁndings. Nanodrop calibration was  also included in the
uncertainty budget for concentration-related effects.Purity of each stock solution was  estimated based on the Bio-
analyzer proﬁle using the proportion of the area under the curve
corresponding to the fragment of the expected length. Fragments
smaller than the expected size may  arise from early termination of
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ranscription or non-speciﬁc transcription from the plasmid back-
one. Longer fragments could be produced due to concatenation
f multiple transcripts or failure of the polymerase to terminate
t the stop site. Therefore, non-speciﬁc fragment peaks may  con-
ain multiple copies of the target sequence, one copy of the target
equence or non-target sequence RNA. Considering this, best and
orst case scenarios of non-speciﬁc fragments containing (a) one
opy of the target sequence (or multiple copies in the case of longer
ragment lengths) or (b) no copies of the target sequence were mod-
lled. The purity was accordingly assigned as the mid-point of the
nterval between the highest and lowest possible content of the
arget sequence considering scenarios (a) and (b) for the material
s a whole. The uncertainty was calculated as the standard uncer-
ainty from the same range (treated as the limits of a rectangular
istribution).
.4.2. RNA copy number ratio
Since both Unknown samples were prepared from the same
RCC stock solutions, common factors such as stock concentra-
ion and purity did not contribute to the uncertainty budget of the
1/U2 RNA copy number ratio. Therefore, the assigned value of
ach ERCC copy number ratio is only the different volumes used to
repare the study Unknowns. The associated measurement uncer-
ainty is composed of precision terms related to the independent
ilution steps performed in the preparation for each Unknown (U1,
2), the calibration uncertainties associated with different volumes
nd sample homogeneity. An example of the calculation process
or the assigned value and uncertainty of ERCC-00013 U1/U2 copy
umber ratio is shown in Supplementary information C Table C.2
hich illustrates the contribution of Unknown 1 (Table C.2A) and
nknown 2 (Table C.2B) to the combined uncertainties (Table C.2C).
.5. Participation in CCQM-P103.1
Thirteen NMIs participated in pilot study CCQM-P103.1 and
eported results for the compulsory measurement of the six ERCC
argets, including one NMI  (CENAM) which submitted results after
he disclosure of the study results (Table 1). Of the participating
aboratories, ten NMIs also submitted results for the optional mea-
urement of the endogenous GOI targets (Table 1).
For ERCC targets, a total of fourteen datasets were submitted by
he thirteen participating NMIs, with one NMI  submitting results
sing both RT-qPCR and RT-dPCR approaches. The fourteen datasets
ere assigned a laboratory ID number on a random basis. For GOI
argets, a total of eleven datasets were submitted, with one NMI
ubmitting results using both RT-qPCR and RT-dPCR approaches,
ith the exception of NES, where one laboratory did not submit a
esult (total 10 datasets).
.6. Analytical methods and instrumentation
The analytical methods, instrumentation and reagents used
y the participating laboratories are summarised in Table 2. The
ajority of laboratories (11 of 14 datasets) used an RT-qPCR
pproach, with two laboratories submitting results generated using
T-dPCR and one laboratory analysing the test materials using a
GS RNA-Seq approach.
The assays used by the 13 laboratories that employed a RT-
PCR or RT-dPCR-based approach utilised the primer sequences
and in the majority cases (10/13), probe sequences) speciﬁed in
he Study Protocol (Supplementary information A). Therefore, dif-
erences between these laboratories’ results are unlikely to stem
rom differences in the speciﬁcity of the assays used, however as
rimers/probes were not supplied by the coordinating laboratory,
ifferences in oligonucleotide synthesis such a puriﬁcation and efﬁ-
iency of dye incorporation are one factor which differed betweenn and Quantiﬁcation 8 (2016) 15–28
laboratories. The majority of these laboratories used hydrolysis
probe chemistry for signal detection, Other differences between
laboratories included 2 sites (# 7 and 13) employing a SYBR Green
intercalating dye qPCR approach and the probes for the endoge-
nous gene target assays used by laboratory 10 were synthesised
using locked nucleic acid (LNA)-bases as opposed to minor groove
binding probes (Table A6).
Of the eleven laboratories performing RT-qPCR, ten laboratories
employed a one-step method, where both RT and qPCR occur in a
single reaction vessel. Eight laboratories used the AgPath One-Step
RT-PCR mastermix speciﬁed in the Study Protocol (Supplementary
information A), whilst the laboratories employing a SYBR Green
approach used a one-step RT-PCR SYBR Green mastermix. One lab-
oratory used a two-step RT-qPCR method, where complementary
DNA (cDNA) is synthesised in a separate reaction prior to qPCR
(Table 2).
Both laboratories performing RT-dPCR quantiﬁed target tran-
scripts using a one-step RT-dPCR approach based on hydrolysis
probe chemistry for end-point detection of ampliﬁed molecules.
In terms of digital PCR instrumentation employed, a ddPCR plat-
form (Bio-Rad) based on droplet PCR was  used by laboratory 8 and a
microﬂuidic chip approach (BioMark from Fluidigm) was employed
by laboratory 12.
Laboratory 11 analysed the study samples using SOLiD (ABI) NGS
method (Table 2). Further details of the NGS library preparation and
instrumentation used are provided in Supplementary information
D.
2.7. Quantiﬁcation and normalisation strategies
Measurements of ERCC RNA copy number ratios by RT-qPCR
were possible using either a standard curve (SC) approach by prepa-
ration of dilution series of the Calibrant material or a relative
quantiﬁcation (RQ) method based on differences in Cq values of the
two Unknown samples [14]. Of the eleven laboratories perform-
ing RT-qPCR, seven measured ERCC copy number ratios using a SC
approach whilst four used a RQ approach (Table 3). dPCR measures
the number of DNA (in this case, cDNA) copies in a sample without
the requirement for a SC [20], (Table 3).
Eleven datasets were submitted with measurements of endoge-
nous GOI targets, using RT-qPCR (eight laboratories), RT-dPCR
(two laboratories) or RNA-Seq (one laboratory) (Table 3). Due to
transcript abundance levels, the Calibrant study material was  not
suitable for the preparation of a SC for measurement of these tran-
scripts; therefore, a RQ approach was  required for analysis of the
endogenous GOI targets by RT-qPCR. Two out of the eight labora-
tories using RT-qPCR applied correction for PCR efﬁciency in copy
number ratio calculations (Table 3). All of the laboratories using RT-
qPCR and RT-dPCR normalised their GOI ratio measurements using
measurement(s) of one or more of the suggested reference genes
(cancer susceptibility candidate 3; CASC3, HPRT1 and ubiquitin C;
UBC), with the majority (seven datasets) applying a normalisation
factor consistent with the GeNorM approach developed by Vandes-
ompele et al. based on the geometric mean of the relative quantities
of all three reference genes [28] and two laboratories applying the
geometric mean of the Cq values (Table 3).
3. Results
3.1. Assigned values, homogeneity and stability of test materialsERCC RNA transcripts were present in U1 and U2 at copy num-
ber ratios between 0.14 and 5.0 and at a range of concentrations
between approximately 103 and 105 copies/L, spiked into a com-
plex background composed of total RNA from Hep-G2, Hs 683
A.S. Devonshire et al. / Biomolecular Detection and Quantiﬁcation 8 (2016) 15–28 19
Table  1
List of BAWG CCQM-P103.1 pilot study participants.
Institute/Organisation Country Endogenous target measurement
AIST Japan No
CENAM Mexico No
INMETRO Brazil Yes
KRISS R. of S. Korea Yes
LGC United Kingdom Yes
NIB Slovenia Yes
NIM P. R. of China Yes
NIMT Thailand Yes
NIST USA Yes
NMIA Australia Yes
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VNIIM Russian Federation 
nd SaOS-2 cells. Table 4 gives the assigned copy number ratio
nd expanded measurement uncertainties. Expanded uncertainties
eﬂect the probable range of ratio values (e.g. 0.14 ± 21%, i.e.  range of
.11–0.17) at a 95% level of conﬁdence and are calculated by apply-
ng a coverage factor (k) to the standard measurement uncertainty
18].
Since the endogenous GOIs were present in the background cell
ine RNAs, it was not possible to assign a RNA copy number ratio to
hese three targets; therefore, the comparability of results for these
argets was assessed relative to a consensus value (Section 3.2.3).
The STS study (Supplementary information B, Fig. B.1) showed
o systematic effects on Cq for the two analysed targets (one ERCC,
RCC-00099, and one endogenous, HPRT1), with the exception of
0 ◦C for the Calibrant sample in assay ERCC-99 (p-value = 0.017),
here an increase in Cq was noted. Therefore it was  ensured that
ll study materials were shipped on dry ice and their condition
hecked upon receipt. No evidence of temperature-mediated insta-
ility was found based on comparison of RNA concentration values
or the two targets during the LTS study (Supplementary informa-
ion B, Fig. B.2), conﬁrming that storage of the samples at −20 ◦C
or the time period covering the duration of the study is accept-
ble. No allowance for sample stability was, therefore, made in the
ssigned values and uncertainties of the test materials (Supplemen-
ary information C).
Differences in the concentration of transcripts between tubes
f the same study materials (“between-unit homogeneity”) were
ssessed by RT-qPCR measurements of the same two targets as the
tability studies (Supplementary information B, Fig. B.3). Results
howed that for ERCC-00099, the between-unit relative standard
eviation (RSD) was 6.1%, 6.8% and 4.4% for Calibrant, U1 and
2, respectively. For HPRT1, the between-unit RSD (to 2 s.f.) was
alculated to be 0.00%, 0.00% and 2.3% for Calibrant, U1 and U2,
espectively. As ERCC-00099 is taken to be representative of the
ther ERCC transcripts in the study materials, a standard uncer-
ainty of 7% (rounded to one signiﬁcant digit) was included in the
easurement uncertainty budget for all ERCC transcripts in all
ypes of material (Supplementary information C). As assigned val-
es were not calculated for the endogenous gene targets, the HPRT1
esults were interpreted as conﬁrmation of acceptable between-
nit homogeneity with respect to the endogenous gene targets.
.2. Participants’ results
.2.1. RNA copy number ratio measurements
The CCQM-P103.1 participants’ results for ERCC RNA copy num-
er ratios along with reported measurement uncertainties (MU)
re given in Table 5. The reported values are displayed graphically
n Fig. 1A–F for ERCC-00013, -00025, -00042, -00099, -00113 and
00171, respectively. The participants’ reported values of the mea-
urand (U1/U2 RNA copy number ratio) for each ERCC target areNo
Yes
Yes
also plotted on log2-transformed scales (Supplementary informa-
tion F, Fig. F.1), with the purpose of reﬂecting the magnitude of
the fold differences between Unknowns. In this study, ERCC-00042,
which is present at a much lower level in U1 than in U2 can be seen
as ‘down-regulated’ in U1, as assigned U1/U2 RNA copy number
ratio of 0.143 corresponds to a 7-fold decrease in ‘expression’ in U1
compared to U2. The difference between the reported RNA copy
number ratio result for each laboratory and the assigned value in
the case of ERCC targets was  assessed for signiﬁcance, taking into
account the reported uncertainty and uncertainty of the assigned
value (Supplementary information G, Table G.1).
ERCC-00013 reported values ranged from 0.66 to 0.84 (Fig. 1A),
and all results with the exception of laboratory 11 (p = 0.03) were
consistent with the assigned value (Supplementary Table G1) and
nine participants reporting values falling within 10% of the assigned
ratio (0.67) (Table 5). For ERCC-00025, U1 and U2 materials were
designed to generate no fold change (an assigned U1/U2 copy
number ratio value of 1.0) (Fig. 1B). All 13 participants’ results (lab-
oratory 14 did not submit a result for this target) were consistent
with the assigned value (Supplementary Table G1), with the 12 RT-
qPCR and RT-dPCR participants reporting ratios within 10% of the
assigned value for ERCC-00025 (Table 5). Reported values for ERCC-
00042 ranged from 0.09 to 0.67 (Fig. 1C) and all results with the
exception of laboratory 11 were consistent with the assigned value
of 0.143 (Supplementary Table G1). Five of the participants (labo-
ratories 2, 3, 5, 6 and 9) reported values within 10% of the assigned
ratio (Table 5). Like ERCC-00025, ERCC-00099 transcript levels in U1
and U2 were also designed to produce no fold change (an assigned
U1/U2 copy number ratio value of 1.0); reported values ranged from
0.88 to 1.14 (Fig. 1D) with all 14 reported results being consistent
with this assigned value (Supplementary Table G1). Eleven of the
reported ratios fell within 10% of the assigned value (Table 5). The
assigned ratio for ERCC-00113 was 3.0 with reported values rang-
ing from 1.91 to 3.27 (Fig. 1E), with all results being consistent with
the assigned value with the exception of laboratory 10 (Supplemen-
tary Table G2) whilst 12 of the participants’ reported values falling
within 10% of this (Table 5). ERCC-00171 U1/U2 RNA copy num-
ber ratio had an assigned value of 5.0; reported values ranged from
3.41 to 9.07 (Fig. 1F) with two results not being consistent with the
assigned value (laboratories 1 and 11) (Supplementary Table G2).
Seven of the participants’ reported ratios were within 10% of the
assigned value (Table 5).
3.2.2. Participants’ results: endogenous gene of interest targets
The CCQM-P103.1 participants’ results for endogenous GOI RNA
copy number ratios with reported uncertainties are given in Table 6
and Fig. 2. When compared with the consensus values and uncer-
tainties for these targets (Section 3.2.3), results from the majority
of laboratories were consistent with the consensus range (Supple-
mentary information G, Table G.2).
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Table 2
Analytical methods and instrumental techniques used by the CCQM-P103.1 participants.
Laboratory ID Method Instrument make &
model
Diluent Carrier RT-PCR approach RT-PCR Master-mix RT priming1 Thermal cycling Primer/Probe
concentration
Reaction (Sample)
volumes2
1 RT-qPCR ABI HT 7900 FAST Water Yes One-step As protocol One-step As  protocol As protocol (2 L)
2  RT-qPCR StepOne (ABI) Yeast tRNA Yes One-step As protocol One-step As  protocol As protocol 15 L
3  RT-qPCR ABI 7500 Water No One-step As protocol One-step As  protocol As protocol As protocol
4  RT-qPCR ABI 7500 Water Yes One-step As protocol One-step As  protocol As protocol As protocol
5  RT-qPCR ABI 7900 HT Water Yes One-step As protocol One-step As  protocol As protocol As protocol
6  RT-qPCR LC480 (Roche) Yeast tRNA (ERCCs
only)
Yes (ERCCs only) One-step As protocol One-step As  protocol As protocol 20 L (2 L)
7  RT-qPCR ABI7900 Water Yes One-step Power SYBR Green
RNA-to-Ct  1  Step Kit
(ABI)
One-step 40 cycles As protocol (primers
only)
20 L (2 L)
8  RT-dPCR Bio-Rad QX100
Droplet  Digital PCR
system
RNA storage solution
(RSS)  (Ambion)
Yes One-step One-Step RT-ddPCR
kit  for Probes
(Bio-Rad)
One-step RT: 60 ◦C 30 min
Hold:  95 ◦C 5 min
PCR:  40  cycles of
(94 ◦C-30 s,
60 ◦C-1  min); Hold
98 ◦C  10 min; Hold
4 ◦C.
As protocol 20 L (5 L)
9  RT-qPCR LC 480 (Roche)
(ERCCs,  2  units)
ABI  7900HT (ERCCs, 1
unit;  GOI)
Water (Calibrant) Yes One-step As protocol One-step As  protocol As protocol As protocol
10  RT-qPCR ANK32, IAP RAS Yeast tRNA No Two-step RT: RevertAid First
Strand  cDNA Synthesis
Kit  (Fermentas)
qPCR: Syntol Reagent
Set  with Buffer B for
PCR
Gene-speciﬁc
(antisense primer
400  nM)
RT: 45 ◦C, 30  min
qPCR:  95 ◦C, 10 min,
(60 ◦C  45  s; 95 ◦C
15  s) × 40 cycles
200 nM primer;
100  nM probe (LNA
probes  endogenous)
RT and qPCR: 20  L
(6  L (RT); 2  L
(qPCR))
11  RNA-Seq SOLiD v4/5500xl N/A3 N/A N/A N/A Random N/A N/A N/A
12  RT-dPCR BioMark 48.770 dPCR
arrays  (Fluidigm)
Water Yes One-step As protocol One-step As  protocol As protocol 5 L (variable)
13  RT-qPCR ABI7900 Water Yes One-step Power SYBR Green
RNA-to-Ct  1  Step Kit
(ABI)
One-step 40 cycles As protocol (primers
only)
20 L (2 L)
14  RT-qPCR ABI HT 7900 FAST RSS (Ambion) Yes One-step As protocol One-step As  protocol As protocol As protocol
1 Gene-speciﬁc for one-step RT-qPCR.
2 If different from study protocol.
3 See Supplementary information D for details of RNA-Seq method.
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Table  3
Summary of quantiﬁcation and normalisation approaches for reported valuesERC.
Target ERCC Endogenous GOI2
Laboratory ID Approach PCR efﬁciency
correction
Approach PCR efﬁciency
correction
Genes used for
normalisation
Normalisation
factor3
1 RQ No RQ No 3 Geometric mean
2  SC N/A1 RQ Yes (mean) 3 Geometric mean
3  SC N/A RQ No 1 (CASC3) N/A
4  RQ No RQ No 2 (CASC3, HPRT1) Geometric mean (Cq)
5  SC N/A RQ Yes (mean) 3 Geometric mean
6  SC N/A RQ No 3 Geometric mean (Cq)
7  SC N/A – – – –
8  dPCR N/A dPCR N/A 3 Geometric mean
9  RQ No RQ No 3 Geometric mean
10  RQ No RQ (MMP1, SLC1A3 only) No 3 Geometric mean
11  NGS N/A NGS N/A No N/A
12  dPCR N/A dPCR N/A 3 Geometric mean
13  SC N/A – – – –
14  SC (ERCC-25 ND) N/A – – – –
1 N/A: not applicable.
2 Laboratories 7, 13 and 14 did not participate in the optional study of endogenous GOIs.
3 Geometric mean of copy number concentration values unless speciﬁed as Cq .
Table 4
Assigned U1/U2 RNA copy number ratio values and uncertainties of ERCC transcripts.
ERCC- Unknown 1
(copies/L)1
Unknown 2
(copies/L)1
U1/U2 RNA copy
number ratio2
Expanded
Uncertainty (k = 2)2
Expanded Relative
Uncertainty (%)
00013 60,000 90,000 0.67 0.14 21%
00025 5000 5000 1.00 0.20 20%
00042 1000 7000 0.143 0.029 20%
00099 70,000 70,000 1.00 0.20 20%
00113 21,000 7000 3.00 0.60 20%
00171 100,000 20,000 5.0 1.0 20%
1 Approximate values (for assigned RNA copy number values,see Supplementary information E).
2 Uncertainties are rounded to 2 signiﬁcant ﬁgures (s.f.) and up to 3 decimal places (d.p.), with corresponding RNA copy number ratio values rounded to the equivalent
decimal  places.
Table 5
ERCC U1/U2 RNA copy number ratios: participants’ results and assigned values.1
1Participants’ U1/U2 RNA copy number ratio and uncertainties were reported to 2 d.p. unless stated otherwise. Values are coloured if they fall within 10% of the
assigned value.
2Expanded measurement uncertainty (for coverage factors (k), see Supplementary Table H2).
3MU was reported to 2 s.f. and U1/U2 RNA copy number ratio was reported to same d.p. as MU.
4ND: Not done.
5Assigned value uncertainties are rounded to 2 s.f. and up to 3 d.p., with assigned U1/U2 RNA copy number ratio values rounded to the equivalent decimal places.
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Fig. 1. ERCC RNA copy number ratios: Participants’ results and assigned values. Reported U1/U2 RNA copy number ratios for ERCC-00013, -00025, -00042, -00099, -00113
and  -00171 (denoted ERCC-13, -25, -42, -99, -113 and -171 in A–F respectively) and expanded uncertainties are shown as reported (linear) values. Approximate copy number
concentration in U1 (as Table 1) are shown in brackets below ERCC target. Log2-transformed values can be found in the Supplementary information, Fig. F1 . Results are
displayed according to method (RT-qPCR (SC, ); RT-qPCR (RQ, circle); RT-dPCR ( ) and NGS ( )) and then ordered numerically by laboratory ID. Solid and
dashed horizontal lines indicate assigned value and expanded uncertainty (k = 2).
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Table  6
Endogenous GOI U1/U2 RNA copy number ratios: participants’ results and consensus values.1
1Participants’ U1/U2 RNA copy number ratio and expanded uncertainties reported to 2 d.p. unless otherwise stated. Values are coloured if they fall within 10% of
the  consensus value.
2Expanded measurement uncertainty (for coverage factor (k) see Supplementary information Table H2).
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Table 7
Analysis of dispersion of participants’ results.
Target n 2 Critical 20.95,n
MMP1 11 5902 19.7
NES 10 1554 18.3
SLC1A3 11 9760 19.7MU was reported to 2 s.f. and U1/U2 RNA copy number ratio was  reported to same
ND: not done.
Consensus value uncertainties are rounded to 2 s.f. and up to 3 d.p., with consensu
Of three GOI targets, MMP1  displayed the largest fold-difference
n transcript level between U1 and U2 (median reported U1/U2 copy
umber ratio value 38.9). The majority of participants reported val-
es within approximately 10% of this value (the ratio of between
5 and 43), although results from laboratories 10 and 11 were out-
ide this range (Fig. 2A). NES displayed the smallest U1/U2 copy
umber ratio (median reported value 1.46), with values ranging
rom 1.22 to 1.64 (−17% and +12% of the median value) (Fig. 2B).
LC1A3 showed an intermediate U1/U2 copy number ratio (median
alue 10.8) compared to MMP1  and NES, with reported ratio val-
es ranging from 5.0 to 15.3 (−53% and +41.9% of the median value)
Fig. 2C).
.2.3. Consensus value estimation
The reported participant laboratories’ estimates of the GOI
1/U2 RNA copy number ratios and associated uncertainties have
 number of features which make the choice of statistical method
mportant if a reliable estimate of the consensus U1/U2 RNA copy
umber ratio value is to be determined:
i. The MMP1  data do not appear to follow a normal distribution
due to the presence of two low RNA copy number ratio values.
This means that a robust method is needed in order to avoid
creating a bias in the result and overestimating the uncertainty.
ii. The reported uncertainties vary considerably between laborato-
ries using the same RT-qPCR method (for example, laboratories
1 and 9 (Table 1)). This suggests that laboratories either did not
take into account the same sources of error or did not treat the
data consistently in evaluating uncertainties (for further com-
ment see Discussion), therefore, methods based on weighting
by uncertainty are not suitable.
ii. The laboratory uncertainties relative to their respective esti-
mated ratios do not account fully for the observed dispersion
between laboratories. This suggests that the uncertainties
themselves are unreliable or that other sources of between-
laboratory variance are present. This is conﬁrmed by 2 analysis
(Table 7): observed 2 values exceed the critical 2 indicating
overdispersion of the laboratories’ results.2 statistics were performed for participants’ results (n) for each of the endogenous
GOIs. The critical 2 value at the 95% conﬁdence interval is displayed in column 4.
The median of the laboratory estimates was calculated and a
standard uncertainty u is based on the median absolute deviation
(MAD) as follows (Eq. (1)):
u = sˆ
√

2n
(1)
where sˆ is the MADe (an estimate of the standard deviation based
on applying a conversion factor of 1.483 to the MAD  to provide
a consistent estimator of standard deviation assuming normality
[29]), the factor
√
(/2) is a correction for the asymptotic efﬁciency
of the median and n is the number of laboratories (Table 8). The
calculated median/MADe values were compared with three other
statistical methods for consensus value estimation, both weighted
and unweighted, in order to illustrate the effect of different choices
of method on the outcome (Table 8). The weighted methods require
a standard uncertainty for each laboratory; however, laboratory
11 provided estimates with asymmetric 95% conﬁdence intervals,
rather than a standard uncertainty. For this case, the mean of
the upper and lower error bar lengths was used to estimate the
expanded uncertainty; this was  then divided by 2 to obtain an
effective standard uncertainty. (Laboratory uncertainties are only
required for weighted methods).
The weighted Huber method [30] is highly inﬂuenced by the
laboratory with the smallest uncertainty, underestimating the
consensus value uncertainty and, perhaps, creating bias in the con-
sensus value in cases where a laboratory deviates substantially
from the majority with respect to its uncertainty. Where there
is substantial over dispersion between laboratories, or outlying
results, the DerSimonian-Laird excess variance approach [31] pro-
duces a larger uncertainty as expected; this is particularly evident in
the MMP1  data. The median/MADe and unweighted Huber Proposal
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Fig. 2. Endogenous GOI U1/U2 RNA copy number ratios: Participants’ results and consensus values. Reported U1/U2 RNA copy number ratios for MMP1, NES and SLC1A3 (A–C
respectively) and expanded uncertainties shown as reported (linear) values. Log2-transformed values can be found in the Supplementary information F Fig. F.2 . Results are
grouped according to method (RT-qPCR (RQ, circle), RT-qPCR (with PCR efﬁciency correction, ), RT-dPCR ( ) and NGS ( )) and then ordered numerically
by  laboratory ID. Solid and dashed horizontal lines indicate consensus value (Section 3.2.3) and expanded uncertainty (k = 2), respectively. Note Laboratory 10 did not submit
a  result for NES (Table 6).
Table 8
Calculation of consensus value and associated standard uncertainty using four methods.
Method Median/MADe Huber estimate
Weighted robust estimate
[30]
DerSimonian-Laird
Excess variance estimate
[31]
Huber M-estimate (Huber
Proposal 2)
Unweighted robust estimate
Target Estimate u Estimate u Estimate u Estimate u
MMP1  38.9 2.0 38.81 0.23 35.4 5.9 37.7 1.8
NES  1.462 0.041 1.612 0.009 1.497 0.041 1.476 0.033
SLC1A3 10.8 1.2 15.10 0.38 10.7 1.7 10.96 0.79
Standard uncertainties (u) are rounded to two s.f. and up to three d.p., with corresponding estimates rounded to the equivalent number.
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 values are quite consistent with each other (Table 8). For these
easons, the median of the laboratory estimates is recommended as
he consensus value with a recommended coverage factor to cover
n approximately 95% interval of k = 2.
. Discussion
In the current study, CCQM-P103.1, six synthetic ERCC and
hree endogenous GOI transcripts were analysed in two blinded
amples (U1 and U2) by 13 NMI  laboratories (10 for GOI targets)
ho reported the U1/U2 RNA copy number ratio for each target.
he aim of the study was to evaluate intra- and inter-laboratory
omparability of methods for mRNA quantiﬁcation, in order to sup-
ort the future development of molecular diagnostic tests based
n the gene expression of multiple mRNA biomarkers. Concor-
ance of participants’ U1/U2 RNA copy number ratio results were
ssessed by comparison with assigned values (for the six ERCC tran-
cripts, mixed at deﬁned ratios) and consensus values (for the three
ndogenous GOI transcripts where the ‘true’ value was  unknown).
The majority of laboratories reported ERCC results which were
ound to be consistent with assigned range of copy number ratio
alues. Likewise, >80% 9 of the 11 of participants results (27 of
2) submitted results for the GOI targets were within the con-
ensus value uncertainty range (Supplementary information G). Of
he ten outlying results, seven were associated with substantial
ifferences in the technique (laboratory 11) or RT-qPCR protocol
laboratory 10) used. The three other outlying results were associ-
ted with lower than average reported measurement uncertainty
relative expanded uncertainty <1%), suggesting that underesti-
ation of the measurement uncertainty was the cause of these
isagreements (laboratory 1). However the majority of labora-
ories reported results were consistent with the assigned values
associated with an uncertainty range of ±∼20%, Table 4). Fur-
hermore >50% of reported values were within 10% of the ERCC
ssigned values. A previous study evaluating the within-laboratory
eproducibility of the 21 genes assayed by the Oncotype Dx test
emonstrated variability of between 0.06 and 0.15 normalised
q units (corresponding to% variation of 4–11% based on assay
fﬁciency of 100%) which took into account between-operator, -
nstrument (of the same make and model) and -days effects [19].
he current study CCQM-P103.1 took into account additional major
ources of variation including laboratory, technique, make/model
f instrument, reaction chemistry, carrier and diluent (Table 2).
herefore the 10–20% variation in results compared to the assigned
r consensus values indicate that RNA copy number ratio measure-
ents for multiple gene targets can be performed reproducibly by
MI laboratories using a validated and established protocol.
The majority of participating laboratories submitted results
sing an RT-qPCR approach and the method suggested in the Study
rotocol (Supplementary information A), including the choice of a
ne-step RT-qPCR approach and use of carrier tRNA (Table 2). The
ain difference in ERCC copy number ratio measurement between
hese laboratories was the choice of a data analysis (SC- or RQ-
ased) approach (Table 3). Whilst the two different approaches did
ot appear to inﬂuence the reported ratios for some ERCCs (ERCC-
0025, ERCC-00042, ERCC-00099), there was a trend for results
rom SC-based measurements to be closer to the assigned values
or ERCC-00013 and -00171 (Fig. 1A and F). This could be due to
ariation in the PCR efﬁciency of the assays for the six targets as
he PCR efﬁciencies of assays for ERCC-00013 (92%) and -00171
87%) (Supplementary Table A6) were further from the ideal value
f 100% than the other 4 targets. A SC approach controls for possible
ifferences in PCR efﬁciency, whilst a RQ method which assumes
CR efﬁciency of 100% (i.e.  doubling of the amount of target inn and Quantiﬁcation 8 (2016) 15–28 25
every cycle in the delta Cq calculation [14]) may overestimate the
magnitude of the fold change if the actual assay efﬁciency is <100%.
There were also differences between the laboratories perform-
ing a SC or RQ approach in terms of their uncertainty calculations
(Supplementary information H). Of the sites performing a SC-
based approach for analysis of ERCC transcripts, some included
the assigned uncertainty of ERCC copy number in the Calibrant
material and SC regression uncertainty in calculating the combined
uncertainty whilst other laboratories did not. Of the eight sites
performing a RQ-based approach for some or all targets (Table 3),
some laboratories calculated uncertainty for the U1/U2 copy num-
ber ratio by combining measures of the variation in individual U1
and U2Cq values (laboratories 1, 4, 5, 6). Others considered the
variation in the U1/U2 ratio as the primary source of uncertainty
(laboratories 2 (GOI), 9, 10). Using a typical RQ approach [14], the
difference between the Cq values of a pair of Unknowns (delta Cq,
related to the U1/U2 copy number ratio) is calculated for each qPCR
experiment. However, in the case that only three ratio values are
available, this limits the degrees of freedom to 2 and necessitates
a large coverage factor k of 4.3. It is also important for both SC and
RQ-based approaches to understand that factors contributing to the
uncertainty in the RNA copy number concentration of each sample
may  not inﬂuence the reported RNA copy number ratio between
samples. For example, the uncertainty in the assigned concentra-
tion of a calibration material should be considered if the reported
result is a RNA copy number concentration value; however, if the
calibration curve is identical for measurements of two  samples
within an experiment, this source of uncertainty does not inﬂuence
uncertainty in U1/U2 copy number ratio. Furthermore, correlation
between the two variables (RNA copy number concentration or Cq
of U1 and U2) should also be taken into account in the calculation
of uncertainty for RNA copy number ratio values [32]. This is par-
ticularly important when the measurement design uses blocking to
compare different samples directly under repeatability conditions,
as it results in more reliable comparison and, therefore, smaller
uncertainties. In this study, not all laboratories took proper account
of this correlation and consequently reported unnecessarily large
uncertainties.
Two  of the laboratories performing a RQ approach included an
allowance for variation in the assays’ PCR efﬁciency in the MU bud-
get. As noted in the preceding paragraph, deviation of efﬁciency
from the theoretical value of 100% will impact on the accuracy of
the ratio calculated using a delta Cq approach [33], therefore, an
allowance for variation in PCR efﬁciency based on dilution series
or expected assay performance parameters should be included
in measurement uncertainty budgets for laboratories using a RQ
approach. For development of RT-qPCR as a higher order measure-
ment procedure, best practice guidelines should be developed with
regard to how different sources of uncertainty should be considered
in value assignment of RNA copy number concentration and ratio
measurements.
The eleven RT-qPCR datasets provide a representative cross-
section of results obtained by this established technique to compare
with more recently developed approaches, namely RT-dPCR and
NGS. RT-dPCR results fell within the assigned range for all six ERCC
transcripts (Fig. 1) and were also close to the consensus values
for the endogenous GOI targets (Fig. 2). A high level of agreement
was also apparent between the two sets of RT-dPCR results using
alternative platforms (BioMark and QX100). Good comparability
between dPCR technologies has been demonstrated for measure-
ments of DNA [34,35], however, this study is the ﬁrst showing good
agreement between dPCR platforms for RNA measurements. It has
recently been shown that deﬁnition of the DNA  copy number con-
centration of a plasmid reference material by dPCR enabled better
inter-laboratory comparability in the results of copy number ratio
measurements (BCR-ABL1/ABL1, % in [36]). The results of P103.1
26 A.S. Devonshire et al. / Biomolecular Detection and Quantiﬁcation 8 (2016) 15–28
Fig. 3. Comparison of U1 and U2 NGS read counts with transcript position. Raw NGS read counts are plotted vs.  nucleotide position for ERCC transcripts (A); and tabulated
according to exon number (B) for GOI transcripts. Total reads for all exons and unprocessed U1/U2 ratios are shown for each GOI (Further analysis of raw read counts
(Supplementary information D) was  performed for values reported in Tables 5 and 6). Position of the RT-qPCR amplicon is indicated in shaded grey (A) and red (B) areas.
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[A.S. Devonshire et al. / Biomolecular D
rovide evidence that RT-dPCR is an accurate method for value
ssignment of RNA-based materials in terms of copy number ratio,
ith such controls enabling RT efﬁciency to be monitored in routine
pplications [7]. RT-dPCR tended to have smaller reported uncer-
ainties compared to RT-qPCR results (Supplementary information
). This may  be due to the fact that dPCR does not require a standard
urve and is not inﬂuenced overtly by variation in PCR efﬁciency,
actors which could increase between-run variability [37,38]. The
T-dPCR results from CCQM P103.1 for mRNA measurements are
lso consistent with a recent study reporting improved precision
f dPCR for microRNA quantiﬁcation [39].
The analysis of the CCQM-P103.1 test materials by NGS (labo-
atory 11) provides a useful test of this technology for quantitative
ranscript proﬁling. The NGS RNA-Seq approach measures sequenc-
ng reads from the entire transcript length whilst RT-qPCR
nd-dPCR based assays measure only approximately 100 bases
ithin the transcript sequence. Whilst the NGS measurements of
ome ERCCs and endogenous targets were close to the assigned and
onsensus values, some U1/U2 copy number ratio measurements,
uch as for ERCC-00042, -00171 and MMP1, were less concordant.
nalysis of the total number of reads (Fig. 3) reveals that lim-
ting read depth and associated imprecision may  be attributable
or discordance in the results for low abundance targets such as
RCC-00042. In addition, positional effects are apparent in the
istribution of reads across the length of transcript, which may
ave contributed to the differences between the NGS and RT-qPCR
esults for ERCC-00171 and MMP1  (Fig. 3). These may  be due to
iases in coverage of some regions of the transcript due to ele-
ents of library preparation, such as sequence-related differences
n RT-priming and sequencing efﬁciency [4].
The uncertainties reported for NGS results were within a sim-
lar range to the RT-PCR-based results for the majority of targets.
he calculation of uncertainties associated with RNA-Seq results
eeds to take into account error associated with the sampling of
eads from within the length of the transcript, for which multi-
le statistical models exist [40,41]. In addition, technical sources of
ariation such as library preparation, which has been found to be
ssociated with increased variation in read counts [4], should also
e considered.
. Conclusions
Pilot study CCQM-P103.1 sets a benchmark in terms of the tech-
ical performance of analytical methods for mRNA quantiﬁcation
nd provides a foundation for the development of a reference sys-
em to support molecular diagnostic tests utilising changes in gene
xpression. By preparing ERCC controls at deﬁned ratios between
he tested samples, concordance of NMI  laboratories’ results could
e assessed with the true values as an indication of methodological
iases. The majority of reported results (>90%) were in agreement
ith the assigned ERCC values, with close to 100% concordance
bserved for laboratories performing a validated RT-qPCR protocol.
he good inter-laboratory reproducibility of the ERCC results was
lso observed with reported values for endogenous GOI transcripts
ithin ∼20% of the consensus values for the majority of NMIs who
articipated in these optional measurements. The RT-qPCR datasets
rovide evidence that both SC and RQ approaches demonstrate
he required accuracy and precision for development as reference
ethods [17] and highlight considerations for uncertainty calcula-
ions for RT-qPCR-based copy number ratio measurements.
While RT-qPCR is recognised as a gold standard for validationf gene expression platforms [42], this study provides evidence
hat the high accuracy, precision and robustness of dPCR for quan-
iﬁcation of DNA can be translated to measurements of mRNA.
hile RT-qPCR and -dPCR methodologies targeted speciﬁc regions
[
[n and Quantiﬁcation 8 (2016) 15–28 27
of a transcript, results using RNA-Seq provided complementary
information on copy number differences for the full length of the
transcript and highlighted that controlling for technical biases is
required in order to improve the accuracy of this technique. As
the study materials were composed of puriﬁed RNA, the study
did not incorporate RNA puriﬁcation from biological matrices.
Sources of pre-analytical variation undoubtedly contribute sig-
niﬁcantly to variability in a complete methodological workﬂow
[43–46], therefore, future studies are required to assess the impact
of pre-analytical factors on measurements of RNA biomarkers.
Development of the capabilities of NMI  and reference laborato-
ries to perform independent certiﬁcation of reference materials and
internal controls for gene expression tests will enable veriﬁcation
of the analytical validity of molecular tests for cancer prognosis
and personalised prediction of treatment efﬁcacy [9] and support
regulation of novel in vitro diagnostic devices [47].
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